Targets › ABCA4
4 programs from 4 companies in 4 trials: 4 Phase 1; Ophthalmology; next expected readout Dec 2026.
Flippase that catalyzes in an ATP-dependent manner the transport of retinal-phosphatidylethanolamine conjugates like 11-cis and all-trans isomers of N-retinylidene-phosphatidylethanolamine (N-Ret-PE) from the lumen to the cytoplasmic leaflet of photoreceptor outer segment disk membranes, where 11-cis-retinylidene-phosphatidylethanolamine is then isomerized to its all-trans isomer and reduced by RDH8 to produce…. (UniProt, P78363)
Open in Phaseline: the race on ABCA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | JWK006 Adeno-associated virus vector expressing ABCA4 gene | ABCA4 | Phase 1 | Stargardt Disease 1 | Dec 2026 |
| VeonGen Therapeutics | VG801 Gene therapy for ABCA4 mutation-associated retinal dystrophy | ABCA4 | Phase 1 | Retinal Dystrophy Due to Biallelic ABCA4 Mutations | Dec 2027 |
| Ascidian Therapeutics | ACDN-01 AAV-based vector carrying DNA construct encoding ABCA4 RNA exon editor | ABCA4 | Phase 1 | Stargardt Disease | Aug 2030 |
| AAVantgarde Bio Srl | AAVB-039 adeno-associated virus (AAV) gene therapy delivering ABCA4 | ABCA4 | Phase 1 | Stargardt Disease | Jul 2032 |
Stargardt Disease (2) Stargardt Disease 1 (1) Retinal Dystrophy Due to Biallelic ABCA4 Mutations (1)
other (2), small molecule (2)
West China Hospital (1) VeonGen Therapeutics (1) Ascidian Therapeutics (1) AAVantgarde Bio Srl (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.